Fig. 7
From: An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs
Post-exposure injection of LVRNA001 to dogs exerted protective efficacy. Dogs were challenged with 50-fold LD50 of the virulent RABV-BD06 strain, six hours later, they were immunized with two doses (0d/7d) or three doses (0d/7d/21d) of LVRNA001 (5 μg or 25 μg), five doses (0d/3d/7d/14d/28d) of inactivated vaccine, or PBS, followed by clinical observation. A The numbers of surviving dogs were recorded and survival rates were calculated. B Neutralizing antibody levels in surviving dogs were analyzed via the FAVN test at 3 months post-challenge. n = 6/group